Google
Trusted Resources: News & Events
Latest announcements and gatherings
Investigational Therapy Altemia Achieves Main Endpoints in Pediatric Sickle Cell Trial
Sancilio Pharmaceuticals says its investigational therapy Altemia (SC411) achieved primary and secondary endpoints in a clinical trial with sickle cell patients 5 to 17 years old. Altemia is a combination of specific lipids designed to restore balance to the membrane of red blood cells that are damaged in sickle cell disease patients. The therapy uses Sancilio’s proprietary Advanced Lipid Technologies (ALT) platform.
The Phase 2 trial (NCT02973360) primary endpoint was the change from baseline in the concentration of fatty acids in the red blood cell membrane of patients treated with one of the three active doses of Altemia, or matching placebo. Fatty acids are a major component of cellular membrane.
+myBinderRelated Content
-
3 Gene Editing Approaches for Sickle Cell DiseaseSickle cell disease (SCD) is a perfect c...
-
Emmaus Life Sciences Receives Validation From European Medicines Agency on Marketing Authorization Application for S...Emmaus Life Sciences, Inc. announced tod...
-
A multi-center, phase-2 trial of losartan for the nephropathy of sickle cell anemiaBackground: Sickle nephropathy (SN) is ...
-
Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemiaSilent cerebral infarction (SCI) is the ...
-
Identifying Outcomes for Sickle Cell Disease Clinical Trials is Aim of coreSCDThe Green Park Collaborative (GPC) is wo...
-
Hardships, and New Hope, for Sickle Cell PatientsSickle cell disease affects about 100,00...
-
Progress in pursuit of sickle cell cureBao, in collaboration with Baylor Colleg...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.